Robotic Arm-Assisted Technology Provides
Surgeons With
Consistently Reproducible Precision in
Hip Replacement Surgery
MAKOplasty Total Hip Arthroplasty is
Designed to Help Surgeons Restore Patient Mobility and
Lifestyle
FT. LAUDERDALE, Fla., Sept. 19, 2011 (GLOBE NEWSWIRE)
-- MAKO Surgical Corp. (Nasdaq:MAKO) today
announced the commercial availability of the RIO® Robotic Arm
Interactive Orthopedic System for use in total hip replacement
procedures, called MAKOplasty® Total Hip Arthroplasty.
MAKO's total hip replacement application is designed to support
the surgeon's ability to more accurately align and position the
implants relative to the needs of a patient. This may reduce
potential complications associated with conventional hip
replacement surgery. MAKOplasty Total Hip Arthroplasty provides a
surgeon with a pre-operative 3-D reconstruction of the patient's
hip and is used to develop the patient-specific surgical plan. The
robotic-arm then assists the surgeon during the procedure to
accurately prepare the joint and optimally place hip implants.
"MAKOplasty Total Hip Arthroplasty provides a significant
advantage to me as a surgeon and to my patients. It provides
quantitative knowledge for what were difficult judgment decisions
inherent in manually performed operations," said Lawrence Dorr,
M.D., founder and medical director of The Dorr Arthritis Institute
in Los Angeles. "When I finish a hip replacement I no longer am
anxious to see the x-ray because I know I've got the implants, leg
length and offset correct. It makes recovery easier for patients,
including their comfort, activities and protection from
dislocation. This robotic guided operation is better for both me
and my patients."
A recently published Massachusetts General Hospital study
reported that, over a sustained period of study of 1,823 hips, only
50 percent of acetabular cups (cup-shaped sockets of the hip joint)
were positioned in the acceptable range. Mal-positioning of
acetabular cups in conventional hip replacement surgery may lead to
impingement that can cause dislocation, fracture, and increased
implant wear.1 Nearly 300,000 primary hip replacement
surgeries are performed annually in the United States using
conventional techniques.
"We're pleased to introduce MAKOplasty Total Hip Arthroplasty as
an option for surgeons who perform total hip replacement," said
Maurice R. Ferrė, M.D., president and chief executive officer of
MAKO Surgical Corp. "We believe that surgeons and patients will
benefit from a technology that can help improve accuracy and
precision in surgery and result in a potential reduction of the
complications reported from conventional approaches."
According to a June 2011 survey conducted by Harris Interactive,
six in 10 adults ages 40+ are afraid they will lose their ability
to walk and/or move around without pain. Nearly nine out of 10
survey respondents thought that hip replacement gives people back
their independence and believe it can restore a better quality of
life.2
"With my hip pain, I really couldn't walk or sleep, and going up
and down stairs was very painful," said Victoria Handy Smudzinski,
44, who has osteoarthritis of the hip and had a total hip
replacement with MAKOplasty. "I'm glad that I had the MAKOplasty
procedure because already I am on my way back to a normal
life."
Approximately 10 million Americans suffer from osteoarthritis
(OA) of the hip, or the wearing away of the cartilage that cushions
the bones of the hips, causing hip pain and stiffness, which can
affect mobility, including walking and bending. Hip OA is the most
common cause of hip replacement surgery.3
MAKOplasty Total Hip Arthroplasty is the newest application for
MAKO's RIO robotic arm system and builds upon five years of MAKO's
existing MAKOplasty Partial Knee Resurfacing procedure for patients
with early to mid-stage osteoarthritis of the knee. MAKOplasty
Total Hip Arthroplasty was cleared for use in the U.S. by the FDA
in February 2010.
About MAKO Surgical Corp. MAKO Surgical Corp.
is a medical device company that markets both its RIO® Robotic-Arm
Interactive Orthopedic system and its proprietary RESTORIS®
implants for orthopedic knee and hip procedures called MAKOplasty®.
The RIO is a surgeon-interactive tactile surgical platform that
incorporates a robotic arm and patient-specific visualization
technology, which enables precise, consistently reproducible bone
resection for the accurate insertion and alignment of MAKO's
RESTORIS implants. The MAKOplasty solution is comprised of
technologies enabled by an intellectual property portfolio
including more than 300 U.S. and foreign, owned and licensed,
patents and patent applications. Additional information can
be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing" or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding, including access to credit, for the purchase of MAKO's
products or cause MAKO's customers to delay a purchasing decision,
changes in competitive conditions and prices in MAKO's markets,
unanticipated issues relating to intended product launches,
decreases in sales of MAKO's principal product lines, increases in
expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, unanticipated issues in
complying with regulatory requirements related to MAKO's current
products or securing regulatory clearance or approvals for new
products or upgrades or changes to MAKO's current products, the
impact of the recently enacted United States healthcare reform
legislation on hospital spending, reimbursement, and the taxing of
medical device companies, loss of key management and other
personnel or inability to attract such management and other
personnel and unanticipated intellectual property expenditures
required to develop, market, and defend MAKO's products. These and
other risks are described in greater detail under Item 1A, "Risk
Factors," in MAKO's periodic filings with the Securities and
Exchange Commission, including MAKO's annual report on Form 10-K
for the year ended December 31, 2010 filed on March 10, 2011. Given
these uncertainties, undue reliance should not be placed on these
forward-looking statements. MAKO does not undertake any obligation
to release any revisions to these forward-looking statements
publicly to reflect events or circumstances after the date of this
press release or to reflect the occurrence of unanticipated
events.
MAKO does and seeks to do engage healthcare professionals and
entities in the development and improvement of our
products. Our policy statement and roster of healthcare
professional partners are available at
http://www.makosurgical.com/site/index.php/company/business-conduct-2.
"MAKOplasty®," "RESTORIS®," and "RIO®," as well as the "MAKO"
logo, whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
1 Clinical Orthopaedics and Related Research.
2011:469(2):319-329.
2 Survey conducted by phone within the United States by Harris
Interactive from June 16-June 20, 2011 among 1,631 adults ages 40
and older. Results were weighted to reflect the U.S. adult
population.
3 AAOS Website
http://orthoinfo.aaos.org/topic.cfm?topic=a00377
CONTACT: MEDIA CONTACTS:
Yvette Cuello
MAKO Surgical Corp.
954-609-5085
mcuello@makosurgical.com
Cynthia Kalb
MAKO Surgical Corp.
954-218-9133
ckalb@makosurgical.com
Lily Eng
Weber Shandwick
415-262-5966
leng@webershandwick.com
INVESTOR CONTACTS:
Susan Verde
MAKO Surgical Corp.
954-628-1706
investorrelations@makosurgical.com
or
Mark Klausner
Westwicke Partners
443-213-0500
makosurgical@westwicke.com
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024